Actinium Pharmaceuticals, Inc. cotiza a 1.06 USD y tiene una capitalización bursátil de $33M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $0.89 | $-0.18 | $-0.19 | $-0.16 |
| Estimado | $-0.20 | $-0.22 | $-0.19 | $-0.32 |
| Sorpresa | +545.0% | +18.2% | +0.0% | +50.0% |
| Métrica | ATNM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -40274.4% | -38.6% | -40235.8% |
| Net Margin | -37652.2% | -33.6% | -37618.7% |
| FCF Margin | -27426.7% | -13.9% | -27412.8% |
| ROE | -432.6% | -40.4% | -392.2% |
| ROA | -65.5% | -32.0% | -33.4% |
| Current Ratio | 6.20 | 2.84 | +3.36 |
| Debt / Equity | — | 0.28 | — |